Multiple sclerosis affects roughly 914,000 people in the United States, according to data from the National MS Society. If you or someone you know lives with MS, you've probably heard about clinical trials—but what are they actually, and why do they matter for MS specifically?
Learn About Paying Your FGUA Bill Online →
A clinical trial is a research study that tests whether a new medical approach works and is safe for people to use. For MS, these trials might test new drugs, physical therapies, rehabilitation techniques, or combinations of treatments. Unlike standard medical care where a treatment is already proven effective, clinical trials investigate treatments that are still being studied. This distinction matters because it shapes how the trial is structured and what participants experience.
MS clinical trials exist because the disease itself varies dramatically from person to person. Some people have relapsing-remitting MS (where symptoms come and go), others have progressive forms, and the severity ranges widely. Researchers need to study how potential treatments work across these different presentations. A drug that helps one type of MS might not help another, which is why so many trials run at any given time.
The landscape of MS research has shifted significantly in recent years. Between 2015 and 2023, the FDA approved 15 new MS drugs—more than double the number approved in the previous decade. This means there are more trials happening now than ever before, exploring both completely new approaches and variations on existing treatments. Understanding this context helps you grasp why learning about trials matters right now for the MS community.
Practical takeaway: Clinical trials are not a last resort or experimental gamble—they're the mechanism through which any new MS treatment reaches the market. Knowing how they work helps you understand your own treatment options and the broader MS care landscape.
Clinical trials follow a specific progression that regulators and the medical field have developed over decades. Understanding these phases helps you know what to expect if you're reading about a particular trial or considering participation. The phases aren't shortcuts—they're safeguards built into the system.
Free Guide to Pay by Plate Illinois Billing →
Phase 1 trials typically involve 20 to 100 people and focus primarily on safety. Researchers are asking: Does this treatment cause serious side effects? What dosage level becomes unsafe? Phase 1 trials often use healthy volunteers, though for some diseases like MS, they may include people with the condition. These trials usually last several months and represent the earliest testing in humans after lab and animal research.
Phase 2 trials expand to 100 to 500 people with the actual condition—in this case, people with MS. Now researchers ask: Does this treatment show signs of working? How many people respond? Which types of MS seem to benefit? Phase 2 trials typically run one to two years. This is where you start seeing whether a promising lab result translates into real benefit for patients.
Phase 3 trials involve 1,000 to 5,000 people and compare the new treatment to either a placebo or an existing standard treatment. These are larger, longer (often two to three years), and more rigorous. They answer the big question: Is this treatment actually better than what we already have? Phase 3 results are what the FDA primarily reviews when deciding whether to approve a new drug.
Phase 4 trials happen after a drug is already approved and on the market. They track long-term effects, compare it to other approved drugs, or explore it for additional uses. Many people taking an MS medication are technically part of ongoing Phase 4 research through safety monitoring and registries.
For MS specifically, trial structure often includes MRI scans to measure brain lesions, disability assessments, relapse tracking, and blood tests. These objective measures help researchers know whether the treatment is working, beyond just how patients feel. Many MS trials also track quality of life, fatigue, and cognitive function because these matter enormously to people living with the disease.
Practical takeaway: When you encounter information about an MS trial, knowing its phase tells you how proven the treatment is. A Phase 2 trial is promising but exploratory; a Phase 3 trial has passed more rigorous testing. This context helps you understand what "promising" actually means in research terms.
If you want to learn about specific trials happening right now, knowing where to look is essential. The National Institutes of Health maintains ClinicalTrials.gov, a free, searchable database of clinical studies conducted around the world. As of 2024, over 15,000 MS-related trials have been registered there since the registry began. This isn't a company or marketing site—it's a government requirement that most clinical trials be registered here.
Free Guide to Mold Removal Methods for Walls →
When you search ClinicalTrials.gov for "multiple sclerosis," you can filter by location, trial phase, recruitment status, and study type. The database shows you the trial's official name, who's running it, what treatment is being tested, what the study is trying to learn, and basic information about who can participate. Each trial has a detailed page with the research team's contact information.
Beyond the government registry, the National MS Society maintains its own trial finder tool specifically designed for people with MS. This tool can narrow results to trials focusing on the specific type of MS you have (relapsing-remitting, progressive, etc.), which matters because not all trials accept all types. The MS Society's database also includes some explanatory information written for patients rather than researchers.
Other organizations also track MS trials. The Multiple Sclerosis Association, Patient Advocate Foundation, and individual disease research organizations often maintain lists of trials recruiting participants. Some academic medical centers and large hospital systems have their own research trial pages. Trial-matching services exist that let you enter your information once and match you with trials seeking people like you, though these vary in quality and transparency.
The information in these registries comes directly from the researchers running the trial. Trial names can be technical and difficult to parse, but every registered trial must include a "plain language" summary explaining what the study does in ordinary terms. The registry also shows the trial's actual status: recruiting, not recruiting, enrolling by invitation, suspended, or terminated. This status matters—a trial that ended early due to success sends a very different message than one that was terminated.
Practical takeaway: ClinicalTrials.gov is your primary source for factual, unfiltered information about MS trials. Learning to navigate it gives you the same trial information that doctors and researchers use. Spending 20 minutes learning how to search and read a trial record on this site saves you hours of less reliable searching elsewhere.
Clinical trials have strict requirements about who can participate. These aren't arbitrary—they exist because the research question often requires a specific group. A trial testing a new drug for early relapsing-remitting MS needs people with that specific diagnosis; including people with progressive MS would muddy the results and waste everyone's time.
How to Delete Your Fitbit Account Guide →
Common requirements for MS trials include confirmed MS diagnosis (usually with documentation), a specific range of disability level, age requirements, and absence of other serious medical conditions that might complicate results. Some trials require that participants have had a certain number of relapses in a set timeframe or that they be on or off specific other MS medications. Pregnancy status, organ function, and previous treatments often matter for safety reasons.
The practical reality of trial participation extends beyond basic requirements. Many trials require frequent visits to a research site—sometimes monthly, sometimes more often. A trial might require brain MRIs every three months, blood draws at multiple timepoints, or daily logbooks tracking symptoms. Some trials use placebo, meaning you might receive an inactive treatment instead of the drug being tested. This is uncomfortable for people hoping the new drug helps them, but it's how researchers know whether improvements come from the treatment or from other factors.
Time commitment varies widely. Some trials last six months; others run for three years or longer. Many require you to commit to staying in the trial for its full duration—you can't just leave early if you decide you're unhappy. Some trials pay participants for their time and travel costs, while others don't. The information section in the trial registry always details these practical elements, though details sometimes emerge only during initial conversations with the research team.
A crucial point: participants can usually withdraw from a trial at any time (though there may be follow-up requirements). If a treatment seems to be harming you, the research team must stop it. If your personal circumstances change and participation becomes impossible, you have
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.